HB 2645 prohibits price gouging on "essential off-patent or generic drugs" in Arizona, which are defined as common, non-patented medications meeting specific criteria (e.g., expired patents, listed by WHO or HHS as essential for serious conditions). It directly affects drug manufacturers and distributors, requiring them to justify price increases of 50% or more within a year - triggered if costs exceed $80 for a 30-day supply or full treatment - by submitting detailed cost breakdowns to the Attorney General. The law allows the Attorney General to investigate, demand corrective actions (like refunding consumers), and impose civil penalties up to $10,000 per violation. It specifically targets drugs used in Arizona’s state medical assistance program (Medicaid), aiming to prevent unjustified price hikes that limit patient access.
HB 2083 requires Arizona health plans (specifically "accountable health plans") to cover medically necessary diabetes equipment and supplies prescribed by a healthcare provider. This includes blood glucose monitors (with special provisions for the legally blind), test strips, insulin, continuous glucose monitors for Type 1 diabetes, syringes, lancets, and other diabetes-related devices. The bill does not mandate coverage for non-medically necessary items, supplies obtained without a prescription, or eliminate cost-sharing like deductibles. It directly affects Arizona residents with diabetes who are enrolled in these specific health plans.
HB 2007 would allow human-use ivermectin to be sold without a prescription in Arizona. The bill directly affects pharmacies, retailers, and consumers who currently need a prescription to purchase human-formulated ivermectin. Its key provision removes the requirement for a prescription or health professional consultation for over-the-counter sale of human-use ivermectin. The bill does not change regulations for veterinary ivermectin or other prescription drugs. (Note: Bill is prefiled for 2025 and not yet enacted.)
